In NHPs, a viral delivery system (AAV) was used to deliver meganuclease [100] and nonviral vectors (lipid nanoparticles) to deliver ABE [101]; they specifically reduce the expression of PCSK9. The results showed that LDL-C levels were significantly reduced for a long time, providing a safe and effective strategy for the treatment of cardiovascular diseases. Here, PCSK9 is linked to cardiovascular disorder.